Rational Design of TP5-Derived Peptidic Inhibitors Targeting GSK3β
Research investigating peptide-based approaches targeting a kinase implicated in pathways associated with neurodegeneration, with potential relevance to Alzheimer's disease.
Conceptual illustration; not actual project simulation data.
Scientific context
Glycogen synthase kinase 3 beta (GSK3β) is a serine/threonine kinase discussed in relation to tau hyperphosphorylation and neurodegenerative processes in Alzheimer's disease. The project examined the rationale for designing peptide inhibitors directed at GSK3β.
The work draws on prior research involving TP5, a peptide derived from the CDK5 activator P35, and its inhibitory effects on CDK5–P25 activity.
Objective & approach
The stated objective was to rationally design novel TP5-derived peptide inhibitors targeting GSK3β, considering the possible relevance of modulating disease-associated signalling.
The work was conducted at the Laboratory of Computational and Structural Biology, Jubilee Centre for Medical Research (JCMR), Kerala, India, from March to September 2025.
Presentations & recognition
- Presented a poster at the National Symposium on Chemical Biology and Drug Design, Jubilee Centre for Medical Research, Thrissur.
- Received First Prize in a poster presentation at the 7th International Conference on Nutraceuticals and Chronic Diseases (INCD-2025), held with the 11th Symposium on Translational Cancer Research, University of Kerala.
- Research content appears in conference abstract proceedings, including the National Symposium's Book of Abstracts (ISBN 978-81-963534-4-5).
Source material & limitations
This page is a high-level summary based on the research title and description supplied in the scientist's CV. Specific computational parameters, binding energies, validation data and final experimental outcomes are not included because source results were not provided for publication.